Noninvasive liver fibrosis markers are independently associated with carotid atherosclerosis risk in patients with nonalcoholic fatty liver disease
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Elevated noninvasive liver fibrosis markers in nonalcoholic fatty liver disease (NAFLD) are linked to increased carotid atherosclerosis (CAS) risk. These markers may help assess cardiovascular disease (CVD) risk in NAFLD patients.
Area Of Science
- Cardiology
- Hepatology
- Medical Diagnostics
Background
- Nonalcoholic fatty liver disease (NAFLD) is an independent risk factor for cardiovascular disease (CVD).
- Carotid atherosclerosis (CAS) predicts cardiovascular events, but its link to NAFLD fibrosis stage is unclear.
- Understanding this relationship can improve CVD risk stratification in NAFLD patients.
Purpose Of The Study
- To investigate the association between noninvasive liver fibrosis markers and CAS risk in NAFLD patients.
- To determine if liver fibrosis markers can predict the presence of carotid atherosclerosis.
- To explore the utility of these markers in assessing cardiovascular risk within the NAFLD population.
Main Methods
- Included 3,302 NAFLD participants, categorized by carotid artery ultrasound (CAS vs. non-CAS).
- Stratified participants into quartiles based on noninvasive liver fibrosis markers: FIB-4, mFIB-4, APRI, AAR, AARPRI, and Forns index.
- Analyzed associations between fibrosis marker quartiles and CAS risk, adjusting for CVD risk factors.
Main Results
- NAFLD patients with CAS had higher blood pressure, glucose, lipids, and noninvasive liver fibrosis marker levels.
- Higher quartiles of FIB-4, mFIB-4, AAR, AARPRI, and Forns index were significantly associated with increased CAS risk.
- These associations remained significant after adjusting for multiple cardiovascular risk factors.
Conclusions
- Increased noninvasive liver fibrosis markers are independently associated with elevated CAS risk in NAFLD.
- These markers may aid in assessing cardiovascular disease risk in individuals with NAFLD.
- Noninvasive fibrosis markers offer a potential tool for CVD risk stratification in NAFLD.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
Related Concept Videos
Endoscopic Ultrasound (EUS) and FibroScan are valuable diagnostic tools in gastroenterology and hepatology, each with specific applications and techniques.
Endoscopic Ultrasound (EUS):
Technological Integration: EUS is a sophisticated integration of optical endoscopy and ultrasonography. The endoscope visualizes the mucosal surface directly, while the ultrasound component penetrates deeper to visualize organs and structures beyond the gastrointestinal wall.
Image Formation: The ultrasound...
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...